Atazanavir-d6

Atazanavir-d6 is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) [2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

Product Specifications

CAS Number

[1092540-50-5]

Product Name Alternative

BMS-232632-d6

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; Isotope-Labeled Compounds; P-glycoprotein; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Purity

99.28

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])OC(N[C@@H](C(C)(C)C)C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(NC([C@H](C(C)(C)C)NC(OC([2H])([2H])[2H])=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2)=O)=O

Molecular Formula

C38H46D6N6O7

Molecular Weight

710.89

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38 (11) :1599-604.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[4]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6 (6) :785-96.